SXTC SXT Pharmaceuticals: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

China SXT Pharmaceuticals specializes in the development of traditional Chinese medicine pharmaceuticals. This EV/EBITDA price chart shows a value of 0.00, which is significant amid trade restrictions forcing the business to operate exclusively within the PRC. Demand for such products remains independent of economic cycles or seasonality. Meanwhile, its micro-cap status triggers investor caution and a certain level of brand image instability.

The investment attractiveness of China SXT Pharmaceuticals (SXTC) is based on stable demand for traditional medicine. An EV/EBITDA multiple of 0.00 assesses the business value, including net debt, relative to operating profit before depreciation and amortization. By analyzing the enterprise value to EBITDA trend, an investor identifies the impact of leverage on capitalization. This indicator helps determine the fair premium for the stability of this cash cow within the pharmaceutical sector.